ABSTRACT

Treatment modification in terms of dose up-titration or supplementary medications is the key requirement for Type-2 diabetes mellitus (T2DM) patients who fails to achieve glycemic targets. This demands treatment strategies including multiple diabetes medications to attain glycemic regulation. Numerous aspects were allied with declining adherence and persistence, comprising polytherapy versus monotherapy régimes. Combination therapy is one strategy to improve adherence, as it is envisioned to condense pill encumbrance, regime intricacy, and costs. This review primarily emphasizes on the dual therapy comprising of incretin-based agents (dipeptidyl peptidase-IV (DPP-IV) inhibitors and sodium-glucose cotransporter-2 (SGLT-2) inhibitors for T2DM treatment. Their mode of action, basis of combination and clinical trial results in support of combining these drugs together for effective management of T2DM. By utilizing the concept of two different patho-physiological mechanisms against diabetes, a noteworthy drop in HbA1c level without any integral menace of hypoglycemia, is achieved by combining these drug categories together. Keywords: Type-2 diabetes mellitus (T2DM), sodium-glucose cotransporter-2 (SGLT-2) inhibitors, dipeptidyl peptidase-IV (DPP-IV) inhibitors, Nanoparticles, HbA1c, hypoglycemia
Publication date: 01/11/2024

https://ijbpas.com/pdf/2024/November/MS_IJBPAS_2024_8450.pdf

Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.11.8450